PredictCan CTO Dr. Sara Cherradi presented the company’s individual-centric DILI platform during the “Revisiting Liver MPS” webinar organized as part of the 3Rs Collaborative and IQ Consortium Webinar Series.
In collaboration with PRADO, PredictCan developed serum-derived educated rat liver spheroids that enable individualized in vitro and in vivo DILI assessment within the same animal, providing richer toxicity data while supporting a substantial reduction in animal use.
PredictCan CEO and co-founder Dr. Hong Tuan Duong joined BFM Business to discuss how individual-centric preclinical models could help move precision medicine earlier into drug development and better account for patient diversity.
Published in Frontiers in Toxicology in collaboration with Centre Antoine Lacassagne, the study demonstrates how PredictCan’s human serum-derived liver models combined with AI can capture chronic and individual-specific DILI while providing clinically relevant risk classification and mechanistic insights.
PredictCan Biotechnologies and PreClinBio Solutions LLP have established a strategic collaboration connecting complementary expertise in preclinical research and human-relevant biotechnology to support translational drug development and strengthen scientific ties between India and Europe.
PredictCan Biotechnologies is participating in a 3Rs Collaborative initiative accepted into the FDA ISTAND program, bringing together regulators, technology providers, and industry end-users to evaluate liver microphysiological systems for drug-induced liver injury assessment.
